Literature DB >> 11206036

Methadone maintenance treatment: is it possible to adapt the daily doses to the metabolic activity of the patient?

C Charlier1, M C Dessalles, G Plomteux.   

Abstract

Controversy still exists concerning the proper daily dose of methadone to be used in opiate dependency treatment. Because it is admitted that serum methadone concentration may be significantly correlated with the amount of drug available at the receptor level, it could be interesting to predict the methadone daily doses necessary to reach such a serum concentration. The authors have attempted to correlate the serum methadone level with the daily intake, considering the metabolic activity of the patients. A poor correlation was found between methadone doses and methadone serum concentrations (r2 = 0.0409, p = 0.048). The test used to determine the metabolic activity of patients is the 6-OH cortisol/17-OH corticosteroids ratio in urine. This urinary 6-OH cortisol/17-OH corticosteroids ratio was tested because cortisol is metabolized through the same P450 cytochromes as methadone, namely cytochrome P450 3A4. This determination could be of interest because it could be tested before methadone administration to predict optimal doses. But when the authors tried to correlate the methadone serum concentration with the steroid ratio, they failed to find a significant correlation (r2 = 0.0046, N.S.), even when they took into account the daily doses (r2 = 0.0015, N.S.), most probably because of some limitations of the cortisol ratio.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206036     DOI: 10.1097/00007691-200102000-00001

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

1.  Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz.

Authors:  Rosario Calvo; John C Lukas; Monica Rodriguez; M Angeles Carlos; Elena Suarez
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

2.  Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

Authors:  David J R Foster; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

Review 3.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.

Authors:  Orna Levran; Einat Peles; Sara Hamon; Matthew Randesi; Miriam Adelson; Mary Jeanne Kreek
Journal:  Addict Biol       Date:  2011-07-25       Impact factor: 4.280

5.  Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

Authors:  Mohammad-Reza Shiran; Martin S Lennard; Mohammad-Zafar Iqbal; Oldwale Lagundoye; Nicholas Seivewright; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

Review 6.  Gender differences in pharmacokinetics and pharmacodynamics of methadone substitution therapy.

Authors:  Manuela Graziani; Robert Nisticò
Journal:  Front Pharmacol       Date:  2015-06-09       Impact factor: 5.810

7.  Methadone Concentrations in Exhaled Breath Condensate, Serum and Urine of Patients Under Maintenance Treatment.

Authors:  Maryam Khoubnasabjafari; Khalil Ansarin; Vahid Jouyban-Gharamaleki; Vahid Panahi-Azar; Samin Hamidi; Zhila Azarmir; Abolghasem Jouyban
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.